- Parties: The applicants were EMD Serono (A Division of EMD Inc Canada) and Merck Serono SA. The respondents were the Minister of Health and Apotex Inc. The interveners were Canadian Generic Pharmaceutical Association (CGPA) and Innovative Medicines Canada (IMC).

- Subject Matter: This judicial review application challenged the Minister of Health's decision purporting to determine that a Canadian patent was reviewed relating to certain drug submission numbers and was found eligible for listing on the patent register.

- Date: The hearing was set on Feb. 6, 2024.

- Venue: This was a federal case before the Federal Court.

- Amount: No financial award was specified.